JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M512595200 on January 10, 2006

J. Biol. Chem., Vol. 281, Issue 11, 7657-7665, March 17, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/11/7657    most recent
M512595200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosenblat, M.
Right arrow Articles by Aviram, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosenblat, M.
Right arrow Articles by Aviram, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Catalytic Histidine Dyad of High Density Lipoprotein-associated Serum Paraoxonase-1 (PON1) Is Essential for PON1-mediated Inhibition of Low Density Lipoprotein Oxidation and Stimulation of Macrophage Cholesterol Efflux*

Mira Rosenblat{ddagger}, Leonid Gaidukov§, Olga Khersonsky§, Jacob Vaya, Roni Oren{ddagger}, Dan S. Tawfik§, and Michael Aviram{ddagger}1

From the {ddagger}Lipid Research Laboratory, Technion Faculty of Medicine, and the Rambam Medical Center, Rappaport Family Institute for Research in the Medical Sciences, Haifa 31096, Israel, the §Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel, and the Laboratory of Natural Medicinal Compounds, Migal-Galilee Technological Center, Kiryat-Shmona 11016, Israel

High density lipoprotein (HDL)-associated paraoxonase-1 (PON1) anti-atherogenic properties in macrophages, i.e. inhibition of cell-mediated oxidation of low density lipoprotein (LDL) and stimulation of cholesterol efflux, were studied using recombinant variants of PON1 and apoA-I expressed in Escherichia coli and reconstituted HDL (rHDL) particles composed of phosphatidylcholine/free cholesterol (PC/FC) and apoA-I. PON1 lactonase activity is stimulated by apoA-I by ~7-fold relative to PC/FC particles. Wild-type (WT) PON1 bound to rHDL inhibited macrophage-mediated LDL oxidation and stimulated cholesterol efflux from the cells to 2.3- and 3.2-fold greater extents, respectively, compared with WT PON1 bound to PC/FC particles without apoA-I. We also tested PON1 catalytic histidine dyad mutants (H115Q and H134Q) that are properly folded and that bind HDL in a similar mode compared with WT PON1, but that exhibit almost no lactonase activity. These could not inhibit macrophage-mediated LDL oxidation or stimulate rHDL-mediated cholesterol efflux from the cells. Furthermore, whereas HDL-bound WT PON1 induced the formation of lysophosphatidylcholine (LPC) in macrophages, the His dyad mutants did not, suggesting that the above anti-atherogenic properties of HDL-associated PON1 involve LPC release. Indeed, enrichment of macrophages with increasing concentrations of LPC resulted in inhibition of the cells' capability to oxidize LDL and in stimulation of HDL-mediated cholesterol efflux from the macrophages in an LPC dose-dependent manner. Thus, we provide the first direct indication that the anti-atherogenic properties of PON1 are related to its lipolactonase activity and propose a model in which PON1 acts as a lipolactonase to break down oxidized lipids and to generate LPC.


Received for publication, November 28, 2005 , and in revised form, January 10, 2006.

* This work was supported by a grant from the Charles & M. R. Shapiro Foundation Endowed Biomedical Research Fund (to D. S. T.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed: Lipid Research Lab., Rambam Medical Center, Haifa 31096, Israel. Tel.: 972-4-854-2970; Fax: 972-4-854-2130; E-mail: aviram{at}tx.technion.ac.il.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Lipid Res.Home page
J. W. C. Brock, A. J. Jenkins, T. J. Lyons, R. L. Klein, E. Yim, M. Lopes-Virella, R. E. Carter, (DCCT/EDIC) Research Group, S. R. Thorpe, and J. W. Baynes
Increased methionine sulfoxide content of apoA-I in type 1 diabetes
J. Lipid Res., April 1, 2008; 49(4): 847 - 855.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
B. Thyagarajan, D. R. Jacobs Jr., J. J. Carr, O. Alozie, M. W. Steffes, P. Kailash, J. H. Hayes, and M. D. Gross
Factors Associated with Paraoxonase Genotypes and Activity in a Diverse, Young, Healthy Population: The Coronary Artery Risk Development in Young Adults (CARDIA) Study
Clin. Chem., April 1, 2008; 54(4): 738 - 746.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
L. Gaidukov and D. S. Tawfik
The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity
J. Lipid Res., July 1, 2007; 48(7): 1637 - 1646.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Deakin, X. Moren, and R. W. James
HDL Oxidation Compromises its Influence on Paraoxonase-1 Secretion and its Capacity to Modulate Enzyme Activity
Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1146 - 1152.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Tanaka, K. Morikawa, Y. Ohki, M. Yao, K. Tsumoto, N. Watanabe, T. Ohta, and I. Tanaka
Structural and Mutational Analyses of Drp35 from Staphylococcus aureus: A POSSIBLE MECHANISM FOR ITS LACTONASE ACTIVITY
J. Biol. Chem., February 23, 2007; 282(8): 5770 - 5780.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. P. Handattu, D. W. Garber, D. C. Horn, D. W. Hughes, B. Berno, A. D. Bain, V. K. Mishra, M. N. Palgunachari, G. Datta, G. M. Anantharamaiah, et al.
ApoA-I Mimetic Peptides with Differing Ability to Inhibit Atherosclerosis Also Exhibit Differences in Their Interactions with Membrane Bilayers
J. Biol. Chem., January 19, 2007; 282(3): 1980 - 1988.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Kriska, G. K. Marathe, J. C. Schmidt, T. M. McIntyre, and A. W. Girotti
Phospholipase Action of Platelet-activating Factor Acetylhydrolase, but Not Paraoxonase-1, on Long Fatty Acyl Chain Phospholipid Hydroperoxides
J. Biol. Chem., January 5, 2007; 282(1): 100 - 108.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
L. Gaidukov, M. Rosenblat, M. Aviram, and D. S. Tawfik
The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux
J. Lipid Res., November 1, 2006; 47(11): 2492 - 2502.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
E. Thomas-Moya, M. Gianotti, A. M. Proenza, and I. Llado
The age-related paraoxonase 1 response is altered by long-term caloric restriction in male and female rats
J. Lipid Res., September 1, 2006; 47(9): 2042 - 2048.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
O. Khersonsky and D. S. Tawfik
The Histidine 115-Histidine 134 Dyad Mediates the Lactonase Activity of Mammalian Serum Paraoxonases
J. Biol. Chem., March 17, 2006; 281(11): 7649 - 7656.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.